Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
NDR InvIT Trust bulk deals : Radhakishan Damani picks Rs 100 cr stake ; Rakesh Jhunjhunwala trust invests Rs 67 cr
23/09/2025
Medicap Healthcare files papers with Sebi for Rs 240-cr IPO
23/09/2025
Nomura sees good times for Indian steel players, picks JSW Steel, Jindal Steel
23/09/2025
Vodafone Idea shares end 4% up ahead of Supreme Court's Friday hearing
23/09/2025
